Royalty Report: Drugs, Delivery, Biotechnology – Collection: 203340

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Delivery
  • Biotechnology
  • Therapeutic
  • Pharmaceuticals
  • Cancer
  • cardiac
  • Disease
  • Immune
  • Food
  • Beverages
  • Nutraceutical
  • HIV / AIDs
  • Vaccine
  • Respiratory

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203340

License Grant
Licensor grants to the Italian Licensee the sole and exclusive license under the Patents and the Know-How to use, offer for sale, sell, develop, manufacture, and have manufactured the Products in the Field in the Territory, with the right to grant sublicenses relating only to Products in the Field in the Territory.
License Property
The patents and know-how are for Liposome Methods and Composition, Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles, Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same,  Stabilizing And Delivery Means of Biological Molecules, Protein-Lipid Vesicles and Autogenous Vaccine Comprising The Same, Nanocochleate Formulations, Process of Preparation and Method of Delivery of Pharmaceutical Agents, Cochleates From Purified Soy Phosphatidylserine, Geodate Delivery Vehicles, Rigid Liposomal Compositions, Cochleate Preparations of Fragile Nutrients, Antisense Cochleates, Cochleates Including Aggregation Inhibitors, Novel Encochleation Methods, Cochleates and Methods of Use, Replacement Enzyme Cochleates, Apoprotein Cochleate Compositions, Cochleate Compositions Directed Against Expression of Proteins, and, Novel Encochleation Methods, Cochleates and Methods of Use.
Field of Use
Field means solely for use of the Products in oncology, cardiovascular and immunology pharmaceuticals.

It is Licensee's intention to use Licensor's licensed, Bioral(TM) nanocochleate drug delivery technology to provide for oral delivery of pharmaceutical products incorporating these compounds.

IPSCIO Record ID: 5541

License Grant
Licensor has grants an exclusive worldwide sublicense to exploit the technology for all opportunities in the processed food and beverage industry for both human and animal consumption.  Both parties are U.S. corporations.  The grant includes the rights to use registered trademark Bioral in connection with the creation of consumable products. Licensee is wholly owned subsidiary of Licensor.
License Property
The technology involves cochleates, cochleate derivatives, and proteoliposomes, and nano-encapsulation.  Cochleate delivery vehicles represent a new technology platform for oral and systemic delivery of clinically important drugs that possess poor bioavailability.

Cochleate delivery vehicles wrap-up or encapsulate the drug, rather than chemically bond with the included drug.  A few of the US patents include 1) Liposome Methods and Composition 4,663,161 2) Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles 4,871,488  Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same 3. Stabilizing And Delivery Means of Biological Molecules 5,643,574.  Exhibit has excellent description of technology.  The exhibit does not explain, but the original licensor is the University of Medicine and Dentistry of New Jersey who granted an exclusive worldwide license to develop the cochleate technology and in some cases co-owns the patents with the corporation.

Trademark 'Bioral'

Field of Use
Field shall mean delivery of Consumable Products to all living systems for processed foods applications for both human and Animal consumption.

IPSCIO Record ID: 266802

License Grant
Licensor grants an exclusive license throughout the Territory, with the right to grant sublicenses to make, use or sell Licensed Technology and Licensed Patents in the Field for research, development and commercialization of one Polynucleotide Product and one ~ Product or Nutraceutical Product.

Licensor grants to a worldwide, non-exclusive license to Licensor Intellectual Property.

License Property
Licensor has rights to certain Licensed Technology relating to cochleates, cochleate derivatives, and proteoliposomes, and nano-encapsulation.

Patented Bioral® is a cochleate drug delivery technology, designed for a potentially broad base of applications.

Field of Use
Licensee recognizes that the Licensed Technology represents a valuable means of delivering Component Products for the use and/or sale in the treatment or prevention of human and/or animal diseases.

'Component Product' shall mean any Polynucleotide Product, Drug Product or Nutraceutical
Product.

IPSCIO Record ID: 7076

License Grant
Licensor hereby grants to Licensee an exclusive license throughout the Territory, with the right to grant sublicenses to make, use or sell Licensed Products in the Field.
License Property
Licensed Product shall mean a Product in the form of (a) antifungal preparations (including Amphotericin B preparations) for mucosal surface application for the indications of chronic sinusitis and asthma; and (b) transmucosal vaccine preparations for the indications of chronic sinusitis and asthma.

Antifungal Products shall mean any and all products covered by the patent rights licensed to Licensee by MAYO.

Technology refers to encochleated formulation of amphotericin B for topical treatments for CRS and asthma.

Licensed Patents

Docket No./Title/

  
Appln No./Patent No.
Country

BSZ-005 Liposome Methods and Composition US 4,663,161

BSZ-005DV Reconstituting Viral Glycoproteins Into Large Phospholipid Vesicles
US 4,871,488

BSZ-006 Protein-or Peptide-Cochleate Vaccines and Methods of Immunizing Using the Same US 5,643,574

BSZ-006CP Stabilizing Delivery Means of Biological MoleculesInt’I (PC) US94/10913

Field of Use
Field shall mean the field of any topical antifungal (including Amphotericin B) for mucosal surface application for the indications of chronic sinusitis and asthma covered by patents licensed to Licensee by the Mayo Clinic (MAYO), and transmucosal vaccine applications covered by a patent held by MAYO for the indications of chronic sinusitis and asthma.

IPSCIO Record ID: 28542

License Grant
Licensor grants to Licensee an exclusive right and license, with a right to sublicense to Affiliates and others in accordance with the provisions hereof, in the Territory under the Licensed Patent and Licensed Information to make, have made, use, import, sell, have sold and offer to sell Licensed Products in the Field.
License Property
Licensor has rights to technology relating to cochleates, liposomes and proteoliposomes which will elicit an antigen specific immune response in humans and which are used in the formulation of human vaccines and has rights to patent applications and patents related to said technology.

Application serial #08/130,986 Protein or Peptide-Cochleate vaccines and methods of immunizing using the same.

Field of Use
Field means vaccines designed to induce (not limited to type of immune modulation) an antigen(s) specific immune response in humans; including vaccines to prevent or treat allergies (Type I hypersensitivity reaction), but not including vaccines to treat autoimmunity nor vaccines made from patient specific antigen(s) for patient specific therapy.

IPSCIO Record ID: 5404

License Grant
Universities hereby grant to us, without the need for any further action, an exclusive license throughout the Territory, with the right to grant sublicenses to manufacture, use and sell Products in the Field, under the Licensed Technology and Licensed Patents. Universities hereby grant to us, without the need for any further action, an exclusive license throughout the Territory, with the right to grant sublicenses to manufacture, use and sell Products in the Field, under the Licensed Technology and Licensed Patents.
License Property
Universities have exclusive rights to certain technology relating to cochleates, liposomes and proteoliposomes.

Under the license agreement, we and the Universities have also jointly patented certain aspects of the cochleate technology and co-own such patents with them.  Our proposed drug delivery technology varies from competitors by encapsulating or wrapping the selected drug in a jellyroll-like structure termed a cochleate cylinder.  All of the components of the cochleate cylinder are naturally occurring substances.  We believe that the cochleate cylinder provides an effective delivery mechanism without forming a chemical bond, or otherwise chemically altering, the drug.   When wrapped in our cochleate cylinders, we anticipate that these drugs may be marketed under our brand name, Bioral.

LICENSED PATENTS

United States Patent Number 4,663,161 Issued May 5, 1987

United States Patent Number 4,871,488 Issued October 3, 1989

United States Patent Application Serial Number 08/130,986 Filed

October 4, 1993. Corres. International Application

PCT/US94/10913 Filed September 30, 1994.

United States Patent Application Serial Number 08/394,70 Filed

February 22, 1995. Corres. International Application, PCT

Field of Use
'Field' shall mean cochleates, liposomes and proteoliposomes for all living systems, including human, animal, plant, microbial, life science, health care, nutrition and cosmetics applications of the Licensed Technology.

IPSCIO Record ID: 5407

License Grant
The Licensor has entered into agreement with the Licensee which is developing several potential products which are vaccine based.
Field of Use
The Licensee wishes to use a combination of liposomes or cochleates in conjunction with Sendai vital proteins and its HIV synthetic peptides to create an EradicAide HIV Vaccine.
The EVP will be used to research and develop such formulation(s) of EradicAide HIV Vaccine to determine feasibility for human clinical trials and eventual marketing.
The Licensee proposes that successful development of EradicAide HIV Vaccine could result in various types of formulations based upon an injectable or oral dosage form
1) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an injectable form
2) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an oral form.

To the extent that the Licensee utilizes the Licensor's Bioral drug delivery technology, Bioral Cochleate Technology seeks to use an established, safe nutriceutical, phosphatidyl serine, to nano-encapsulate by means of our patented Cochleate structures, drugs to achieve oral delivery of therapeutic nutriceuticals that normally require injection (such as molecules with poor water solubility, large hydrophilic molecules, and protein and peptide biopharmaceuticals) and to potentially reduce toxicity and side effects frequently associated with established therapeutics.

IPSCIO Record ID: 291110

License Grant
Canadian Licensor hereby grants to Licensee an exclusive license for the Field in the Territory under the Licensed Patents; and an exclusive license for the Field in the Territory under the Know-How; for the sole purpose of developing, making, having made, importing, using, offering for sale and selling Licensed Product in the Territory, including the right to grant sublicenses under these rights as set out in this Agreement.
License Property
Licensed Product means Ciprofloxacin encapsulated in the Licensor Liposome Technology and which is intended for pulmonary delivery.

Ciprofloxacin means the chemical compound known as ciprofloxacin, whose more specified chemical name is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid and all pharmaceutically active salts thereof.

AERx Device means the durable hand-held device developed by Licensee for the delivery of Ciprofloxacin by inhalation and known as the AERx Device, as such device may be modified pursuant to the Agreement.

Loading Patents means the patents owned by University and exclusively licensed to Licensor and set out in Agreement.
5,800,833 – Method for loading lipid vesicles
5,785,987 – Method for loading lipid vesicles

Sphingosome Patents means the Patents owned by Licensor and set out in this Agreement.
5,543,152 – Sphingosomes for enhanced drug delivery

Licensed Patents means the Loading Patents and the Sphingosome Patents.

Patent means (a) all patent applications filed or having legal force in any country owned or controlled by Licensor as of the Effective Date; (b) all patents that have issued or in the future issue therefrom owned or controlled by Licensor as of the Effective Date, including without limitation utility, model and design patents and certificates of invention; and (c) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions (including supplemental protection certificates), additions, registrations or confirmations to or of any such patent applications and patents.

Licensor Liposome Technology means Licensor’s proprietary liposomal drug delivery system that encapsulates drugs in sphingomyelin/cholesterol liposomes using a proton gradient generated by either an ionophore or methylammonium sulfate.

Field of Use
This agreement pertains to patented liposomal formulation technology for the pulmonary delivery of ciprofloxacin

Ciprofloxacin is a fluoroquinolone (flor-o-KWIN-o-lone) antibiotic that fights bacteria in the body. It is used to treat different types of bacterial infections, including skin infections, bone and joint infections, respiratory or sinus infections, urinary tract infections, and certain types of diarrhea.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.